Mastocytosis
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AS
AB ScienceFrance - Paris
2 programs2
masitinibPhase 2Small Molecule1 trial
masitinibPhase 2Small Molecule1 trial
Active Trials
NCT00831974Completed
Blueprint MedicinesMA - Cambridge
1 programMast Cell Connect: A Registry for Patients With MastocytosisN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AB Sciencemasitinib
AB Sciencemasitinib
Blueprint MedicinesMast Cell Connect: A Registry for Patients With Mastocytosis
Clinical Trials (3)
Total enrollment: 743 patients across 3 trials
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation
Start: Feb 2007Est. completion: May 2010
Phase 2Completed
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis
Start: Oct 2004
Phase 2Completed
Mast Cell Connect: A Registry for Patients With Mastocytosis
Start: Nov 2015Est. completion: Jan 2021743 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space